Immunowake, Inc. founded by WU Xiaoyun, a senior expert in the field of antibody drugs, is biotechnology research and development company. Its core technology is BiART platform technology to develop bispecific antibody drugs. This technology differs from the existing global research & development ideas, has global intellectual property rights and solves the common problem of critical defects of bispecific antibody drugs under research. It is expected to develop a series of new-type antibody drugs with breakthrough efficacy and realize the upgrading and updating of antibody drugs.
At present, a series of drugs derived from the platform have begun animal experiments in the United States, and preliminary pharmacodynamic evaluation at the animal level is expected to be completed in the near future.